Loading clinical trials...
Loading clinical trials...
A Double Blind, Double Dummy, Randomised, Multicentre, Two Arm Parallel Group Study to Assess the Efficacy and Safety of FLUTIFORM® pMDI (2 Puffs Bid) vs Seretide® pMDI (2 Puffs Bid) in Subjects Aged ≥12 Years With Moderate to Severe Persistent, Reversible Asthma
Conditions
Interventions
Fluticasone/ Formoterol
fluticasone/ salmeterol
Locations
1
China
China-Japanese Friendship Hospital
Beijing, Beijing Municipality, China
Start Date
June 2, 2017
Primary Completion Date
December 30, 2019
Completion Date
March 30, 2020
Last Updated
April 29, 2019
NCT07219173
NCT02327897
NCT07486401
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
Mundipharma (China) Pharmaceutical Co. Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions